Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — H.C. Andersen Capital Institutional Seminar (September 2025)
13 slides from Expres2ion Biotech Holding Ab's conference presentation, Sep 18, 2025
Slide 1: Innovative vaccines for cancer and infectious diseases
_ oS exBHBS Zion | Keith Alexander — CFO ym 18 September 2025 =s Innovative " vaccines for Hosted by Sitiaea.s i") STO: EXPRS2 a... ExpreS2ion Biotech Holding AB atip Seay “
Slide 2: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
Slide 3: Breast Cancer: High Burden & Significant Unmet Needs
Breast Cancer: High Burden & Significant expression Unmet Needs 7 . : HER2 expression _ Annual new breast cancer cases’® * 2.3 million women diagnosed each year! — the : HER2 H most common cancer globalll im receptor | 1,400,000 g y H HER2 receptors | * 685,000 annual deaths! — the leading cause of
Slide 4: Large Addressable Market in HER2-Positive Cancers
Large Addressable Market in HER2-Positive expresion Cancers ES2B-CO001: First-in-Class HER2 immunotherapy, targeting the full HER2 extracellular domain Patient distribution by region and cancer type! (> } Global market size: The Breast cancer therapy 1 market is €27B globally with a projected 7% ,00
Slide 5: Major Deals Underscore Big Pharma Interest in HER2 Therapies
Major Deals Underscore Big Pharma Interest in HER2 Therapies Multiple MSA and licensing deals in HER2-expressing cancer therapies have reach multi- billion-dollar values, especially for drugs in first- or second-line use Key transactions Year [Product -genericname | Phase [Seller |Acquirer_ | Up-fro
Slide 6: We Are a Platform-Based Immunotherapy Company
We Are a Platform-Based Immunotherapy Company expreSceion BIOTECH Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Pre-clinical Pharmacology Target DISEASE Project/Target ID Identification cGMP / Tox Phase | Breast cancer ES2B-CO01/HER2-VLP Malaria: Blood
Slide 7: ES2B-C001: Novel HER2 Vaccine
ES2B-CO01: Novel HER2 Vaccine — expres eae Differentiated Mechanism of Action Targets full HER2 ECD to produce a polyclonal antibody response (all 4 extra- celular domains) Virus-Like Particle (VLP) technology enhances immunogenicity = 50 HER? molecules) Polyclonal antibody response triggers all maj
Slide 8: Broad polyclonal immune response advantage over monoclonal antibodies
• • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b and IgG3, which were previously found to be instrumental in the protection of transgenic mice from HER-2 expressing tumors [31,
Slide 9: Clinical Development Underway — Path to Proof-of-Concept
expreSeion Clinical Development Underway — gion Path to Proof-of-Concept eee + First three patients dosed * Initial immune response data available from first patient only; showed HER2-specific antibodies (broke tolerance) * Data from additional patients pending 2025 2026 2027 2028 2029 2030 2031 203
Slide 10: Experienced Leadership with Oncology & Vaccine Expertise
Experienced Leadership with Oncology & exprescion Vaccine Expertise Executive Management Fully capable of Bent U. Frandsen CEO 30 years life science management, L i : business development and f % wh FR | | Grocers executing to MSc, Copenhagen Business School pyainess cievelopment and finance “ALK 4)
Slide 11: Financial & Runway — Funding Development with Discipline
Financial & Runway — Funding Development —s**P"® S28 with Discipline Operating income, SEK ‘000s Net sales Other operating income +42% YoY 2,000 1,000 1 r fe) 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 -10,000 -15,000 -20,000 -25,000 * Revenue and grants: Recurring income offsets burn * Cost control: Operating c
Slide 12: Investment Highlights — Building Value in Immuno-Oncology
Investment Highlights — Building Value in Immuno-Oncology ¢ Large unmet medical need * Differentiated therapeutic approach ¢ Strong preclinical proof-of-concept * Clinical progress & upcoming catalysts * Significant market & revenue potential ¢ Experienced team & partnerships ¢ Financially prudent w
Slide 13: Q&A
expreSceion 5 BIOTECH Q&A EXPRS2 Innovative vaccines for a F investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — H.C. Andersen Capital Institutional Seminar (September 2025) on 6ix